Merck Has Agreed To Acquire CN201, An Investigational Clinical-stage Bispecific Antibody For B-cell Associated Diseases, From A Privately Held Curon Biopharmaceutical For An Upfront Payment Of $700M In Cash And Up To $600M In Milestone Payments
Portfolio Pulse from Benzinga Newsdesk
Merck has agreed to acquire CN201, an investigational bispecific antibody for B-cell associated diseases, from Curon Biopharmaceutical for $700M upfront and up to $600M in milestone payments. CN201 is in Phase 1 and Phase 1b/2 trials for non-Hodgkin's lymphoma and B-cell acute lymphocytic leukemia, showing promising preliminary data.
August 09, 2024 | 10:48 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merck's acquisition of CN201 from Curon Biopharmaceutical for $700M upfront and up to $600M in milestone payments could enhance its portfolio in B-cell associated diseases. CN201 shows promising preliminary data in early trials for NHL and ALL.
The acquisition of CN201, which shows promising preliminary data in treating B-cell associated diseases, could significantly enhance Merck's portfolio and future revenue streams. The upfront and milestone payments indicate a strong commitment to this asset.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100